Data from Centocor Inc.'s Phase III CAPTURE trial suggest that treatment with CNTO's ReoPro abciximab antiplatelet antibody benefits only a subset of patients with unstable angina who undergo angioplasty. But rather than narrowing the market for ReoPro, CNTO believes that the stratification of patients based on risk will provide more clinical benefit and solidify use of the drug.

The data, published last week in the New England